Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's FY 2025 revenue rose about 45% to $65.2B and net income more than doubled to nearly $21B; the article favors Lilly for 2026, citing expected revenue growth of more than 30% to $88.6B and GLP-1 products Zepbound and Mounjaro. Bristol Myers Squibb reported FY 2025 revenue of about $48.2B, down roughly 0.2%, but net income recovered to $7.1B from a $8.9B loss in 2024; the article notes pricing, patent and pipeline risks despite its lower valuation. Lilly trades at 33.8x forward earnings versus Bristol Myers' 8.2x, and the author says Lilly's growth prospects justify the premium.

Analysis

The key asymmetry is not simply value versus growth: LLY’s premium depends on converting exceptional GLP-1 demand into durable, profitable volume despite payer bargaining, manufacturing constraints and entrants. Oral and direct-to-consumer channels could expand the addressable market, but may also shift mix toward lower net prices; access gains are not automatically margin gains. Distribution through MCK, COR and CAH does not by itself imply meaningful earnings upside for wholesalers, whose economics depend on contract terms and volumes rather than drug sales growth alone.

BMY’s low multiple offers a cushion only if cash generation and newer-product growth bridge patent and pricing erosion. A headline earnings rebound is less informative than the durability of free cash flow and product-level replacement revenue. The article’s optimistic projections and valuation comparisons are not independently verified here; confirm guidance, net pricing and product attribution before trading.

Near term, the market is likely to reward LLY execution and punish any supply, access or guidance disappointment. Over 1–3 months, monitor capacity commentary, realized net pricing and prescriptions; over 6–18 months, competitive launches and BMY’s revenue replacement determine whether the valuation gap narrows. Contrarian risk: treating GLP-1 demand as purely volume growth overlooks payer leverage and price/mix, while treating BMY as a simple yield play overlooks the possibility that cash flows erode faster than the multiple discounts.

Key Decisions for Investors

• Do not chase LLY solely on the growth narrative. For an existing position, consider a defined-risk collar or trim into strength if valuation exposure is already large; reassess after evidence on capacity, net pricing and guidance. Falsifier: sustained volume growth accompanied by stable net pricing and raised outlook.
• Keep BMY on a watchlist rather than buying only for its yield or low multiple. Require evidence that newer-product growth and free cash flow offset legacy-product erosion; cut the thesis if guidance or cash generation weakens.
• A small, hedged long-BMY/short-LLY relative-value position is a conditional valuation-convergence trade, not a view that BMY has superior fundamentals. Size conservatively: LLY’s growth could continue to outrun multiple compression. Exit if BMY’s replacement revenue disappoints or LLY continues raising medium-term expectations.
• Treat MCK, COR and CAH as monitoring names, not automatic beneficiaries. Verify distributor contract economics and incremental volume before expressing a GLP-1 read-through through these stocks.